Statin Therapy in Patients With Early Stage ADPKD

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study plans to learn if pravastatin is helpful in slowing down the progression of kidney disease in adults with autosomal dominant polycystic kidney disease (ADPKD). Pravastatin has been approved by the Food and Drug Administration (FDA) for adults for treatment of hyperlipidemia (high cholesterol levels). The investigators are using pravastatin in this study as an investigational drug for treatment of ADPKD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Colorado, Denver
• Treatments: Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pravastatin

Criteria

Inclusion Criteria:

• Diagnosis of ADPKD

• Total kidney volume >500 mL

• Estimated glomerular filtration rate (GFR) ≥60 mL/min/1.73m^2

• Controlled blood pressure <140/80 mmHg

Exclusion Criteria:

• Uncontrolled hypertension

• Diabetes mellitus

• Renal disease, renal cancer, single kidney, recent renal surgery, or acute kidney injury

• Unstable angina

• Coronary artery disease

• Prior ischemic stroke

• Other clinical indication for a statin

• History of hospitalizations within the last 3 months

• Hepatic impairment or liver function abnormalities

• Secondary hypercholesterolemia or hypocholesterolemia

• Use of tolvaptan, gemfibrozil, other fibrates, niacin, clarithromycin, or cyclosporine

• Hypersensitivity to statins

• Immunosuppressive therapy within the last year

• Clinical contraindication for an MRI (i.e. implants, pacemaker, claustrophobia)

• Hypersensitivity to iodine

• Pregnant or breast feeding

• Current tobacco use

• Alcohol abuse or dependence